SCIENCE@home

There’s Much Yet to be Done: Diverse Perspectives on HPV Vaccination

G. Zimet,N. Osazuwa-Peters

Published 2019 in Human Vaccines & Immunotherapeutics

ABSTRACT

It has been over 10 y since the first HPV vaccines were licensed and introduced in a number of countries around the world. As only the second vaccine (after hepatitis B) that prevents an infection that can lead to the development of cancer, HPV vaccine occupies an important position in our armamentarium of vaccines yet remains underutilized. The number of national HPV vaccination programs has increased steadily; as of June 2017, 91 countries had introduced national HPV vaccination programs, with that number now over 100. Over the past 10+ y, several modifications have been made to the vaccination regimen (e.g., moving from three to two doses if the first dose is administered before age 15 y), in the type of vaccine available (e.g., introduction of the 9-valent vaccine), and in the target of vaccination (e.g., many countries have shifted from female-only to gender-neutral vaccination). There is great variability across the globe in terms of HPV vaccination policies and accompanying barriers to the implementation and/or sustainability of programs. It is well known, for instance, that Japan’s initial success with vaccination was undermined by several factors, leading to a precipitous drop in vaccination rates, with little subsequent recovery. Other countries, such as the U.S., have struggled to achieve vaccination goals, and still others have faced setbacks but with good recovery (e.g., Denmark and Ireland). At the same time, many countries, including China, still have not implemented national vaccination programs, with the cost of vaccines presenting a significant obstacle, particularly for those countries that are not eligible for reduced pricing through Global Alliance for Vaccines and Immunisation (GAVI) or other mechanisms. Other countries, such as Malaysia, Rwanda, Australia, and the U.K., have achieved sustained high levels of vaccination. Unwarranted fears about HPV vaccine and the proliferation of misinformation, particularly via social media, have proven to be significant and widespread obstacles to achieving andmaintaining high vaccination rates. This special issue of Human Vaccines & Immunotherapeutics brings together a number of timely articles covering several topic areas related to HPV vaccination. Included among these are papers focused on: social media and the Internet; vaccination policy; interventions to improve vaccination rates; new domains related to HPV vaccine knowledge, attitudes, and behaviors; alternative settings for vaccine delivery; HPV prevalence, incidence, and type distribution among specific populations; HPV-related oropharyngeal cancers (OPC), vaccine characteristics; and cost-effectiveness modeling. The 68 papers in this special issue include research papers, reviews or policy pieces, short reports, and commentaries.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-86 of 86 references · Page 1 of 1

CITED BY

Showing 1-12 of 12 citing papers · Page 1 of 1